What Sebia does

Sebia is a global In Vitro Diagnostic (IVD) company founded in 1967 and headquartered in Evry, France, specializing in clinical protein electrophoresis equipment and reagents. The company provides a comprehensive portfolio of instruments, tests, software, and services to clinical diagnostic laboratories across 120+ countries, with 20,000+ installed instruments and 1,300+ employees worldwide. Its core technology platforms include Capillary Electrophoresis (CAPILLARYS 3 family, MINICAP), Gel Electrophoresis (HYDRASYS 2), IFA automation (dIFine microscope with AI-powered pattern recognition), and random-access ELISA (Alegria 2 with 130+ tests). The proprietary PHORESIS software manages data analysis across electrophoresis instruments, while Sebia Academy, Sebia Lean Service, and Sebia Service provide education, optimization, and technical support.

The company's test menu addresses five primary clinical areas: oncology (Multiple Myeloma diagnosis via serum protein electrophoresis, immunofixation, immunotyping, and Free Light Chains with 96.8% concordance to IMWG criteria), metabolic disorders (HbA1c for diabetes, CDT for alcoholism), hemoglobinopathies (newborn and patient screening covering 500+ variants), autoimmune diseases (ANA, ANCA, vasculitis, connective tissue disease panels), and infectious diseases. Sebia holds regulatory clearances including FDA approvals for FLC Kappa & Lambda assays (2024) and CAPILLARYS 3 DBS (2024), plus IFCC standardization for CDT testing.

Sebia's business model combines hardware sales (instruments) with high-margin recurring revenue from proprietary test reagents and consumables tied to the installed instrument base, supplemented by service and education revenue. The company distributes through a global direct enterprise sales force targeting clinical laboratories, with integration partnerships with major lab automation vendors (Inpeco FlexLab, Siemens Healthineers Aptio, PerkinElmer). The company is privately held, with private equity firms CVC Funds, La Caisse, and Téthys Invest as existing investors; in late 2025, Warburg Pincus announced acquisition of a significant minority stake (EC-approved December 2025, closing expected Q1 2026). Sebia has pursued an active M&A strategy, acquiring Orgentec Diagnostika (2021) and ZEUS Scientific (2022) to expand autoimmune and infectious disease capabilities, and entered a strategic partnership with ABIONYX Pharma (2025) for sepsis diagnostics development.

Name

Sebia

Legal name

Sebia S.A.

Website

https://sebia.com

Company type

Private

Founded year

1967

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Sebia is a global In Vitro Diagnostic company specializing in clinical protein electrophoresis instruments, reagents, and autoimmune disease tests, serving clinical diagnostic laboratories across 120+ countries with 20,000+ installed instruments and a recurring reagent revenue model.

Ownership category

akta.pro rank

Product category

In Vitro Diagnostics (Clinical Laboratory Equipment and Reagents)

NAICS

Analytical Laboratory Instrument Manufacturing (334516), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Hematology & Coagulation Diagnostics (HLAHAAAB)

akta.pro secondary industry

IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)

Keywords

• In vitro diagnostics
• Capillary electrophoresis
• Protein electrophoresis
• Diagnostic reagents
• Clinical laboratory equipment

Headquarters

HQ city

Norcross

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. IVD Instruments and Hardware: Sale of electrophoresis instruments including CAPILLARYS family, MINICAP, HYDRASYS, dIFine, and Alegria 2 systems to clinical laboratories.
2. Diagnostic Reagents and Tests: Recurring revenue from proprietary test reagents, consumables, and assay kits for the installed instrument base covering protein electrophoresis, immunotyping, FLC, HbA1c, hemoglobin, CDT, autoimmune and infectious disease tests.
3. Service and Support: Sebia Service for technical and scientific support, Sebia Lean Service for laboratory performance optimization, and Sebia Academy for customer education.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Sebia manufactures and sells in vitro diagnostic instruments (capillary electrophoresis, gel electrophoresis, IFA automation, and random-access ELISA systems), proprietary test reagents and consumables, the PHORESIS data analysis software, and laboratory support services for clinical diagnostic laboratories worldwide. Its test portfolio spans multiple myeloma, diabetes, hemoglobinopathies, autoimmune, and infectious disease diagnostics, with 20,000+ instruments installed in 120+ countries.

Product overview

Sebia is a global specialized In Vitro Diagnostic company providing a comprehensive portfolio of instruments, tests, software, and services for clinical diagnosis laboratories. The core technology platform includes Capillary Electrophoresis instruments (CAPILLARYS 3 family, MINICAP), Gel Electrophoresis (HYDRASYS 2), IFA automation (dIFine microscope and P30 processor), and random-access ELISA (Alegria 2). These instruments run tests across key clinical areas: Oncology (Multiple Myeloma diagnosis via serum protein electrophoresis, immunofixation, immunotyping, and Free Light Chains), Metabolic Disorders (HbA1c for diabetes, CDT for alcoholism), Hemoglobinopathies (newborn and patient screening), and Autoimmune/Infectious Diseases (ANA, ANCA, anti-CCP, anti-MCV, thyroid, celiac, vasculitis panels). The proprietary PHORESIS software manages data analysis across electrophoresis instruments, while Sebia Academy, Sebia Lean Service, and Sebia Service provide education and support. Acquired brands include Orgentec (autoimmune/infectious disease ELISAs) and Zeus Scientific. The MySebia portal provides customer self-service access.

Differentiator

Problem solved

Functional benefit

Brands

• Orgentec: Brand under Sebia offering for autoimmune and infectious disease diagnostic tests, including ORG-prefixed products.
• dIFine
• Alegria 2
• CAPILLARYS
• HYDRASYS

Products and services

• CAPILLARYS 3 TERA TLA High-throughput capillary electrophoresis instrument with total lab automation connectivity to Inpeco FlexLab and Siemens Healthineers Aptio tracks, processing up to 87 protein electrophoresis results per hour. For high-volume clinical diagnostic laboratories.
• CAPILLARYS 3 TERA Multiparametric capillary electrophoresis instrument combining precision, high-quality separation, and high throughput for protein electrophoresis, immunotyping, and HbA1c testing. For medium-to-high volume clinical laboratories.
• CAPILLARYS 3 OCTA Capillary electrophoresis system for medium-to-high volume laboratories requiring multiple simultaneous electrophoretic separations.
• CAPILLARYS 3 DBS FDA-cleared automated capillary electrophoresis instrument dedicated to newborn hemoglobin disorders screening using dried blood spots, with up to 70 samples/hour throughput and full traceability from sample punch to result. For newborn screening programs.
• MINICAP FLEX-PIERCING Compact, fully automated capillary electrophoresis instrument for small-to-medium size laboratories offering seven available techniques including protein, immunotyping, HbA1c, hemoglobin, and CDT testing.
• dIFine automated microscope Fully automated IFA microscope with AI-powered ANA pattern recognition using computer vision, processing up to 96 fields per run at 8 seconds per well, with integrated image atlas for ICAP-compliant pattern validation. For autoimmune disease testing laboratories.
• dIFine P30 processor Walk-away benchtop instrument for automated IFA slide processing, handling up to 240 samples and 30 slides per run with full traceability from dilution to cover slipping. For autoimmune and immunology laboratories.
• HYDRASYS 2 SCAN FOCUSING Semi-automated gel electrophoresis instrument for isoelectrofocusing and immunofixation, used with HYDRAGEL kits for CNS IgG oligoclonal band detection in multiple sclerosis diagnosis. For clinical laboratories performing neurological disease testing.
• Alegria 2 Fully automated random-access ELISA-based analyzer using Monotest technology for autoimmune and infectious disease diagnostics, offering a customizable panel of over 130 tests with continuous loading and on-board quality control. For clinical autoimmune and infectious disease laboratories.
• PHORESIS Software Proprietary data analysis and interpretation software for Sebia electrophoresis assays, facilitating efficient result management and analysis across all Sebia instruments. For clinical laboratories running Sebia instruments.
• Free Light Chains (FLC) Kappa & Lambda FDA-cleared ELISA assay for quantification of kappa and lambda free light chains in serum, used as an aid in diagnosis and monitoring of Multiple Myeloma and AL amyloidosis with 96.8% concordance to IMWG criteria. For clinical laboratories and oncology departments.
• Carbohydrate Deficient Transferrin (CDT) IFCC-standardized biomarker test for chronic alcohol abuse detection using capillary electrophoresis, with CDTIFCC percent value automatically calculated. For clinical and forensic laboratories.
• Hemoglobin Disorders Screening Capillary electrophoresis-based hemoglobin variant screening enabling high-resolution separation of Hb S, C, D, and E variants with accurate quantification of Hb A2 and Hb F, covering over 500 hemoglobin variants. For newborn screening and hemoglobinopathy reference laboratories.
• CNS Local IgG Synthesis Detection by Isoelectrofocusing Gold standard assay using HYDRAGEL CSF ISOFOCUSING kit on HYDRASYS 2 for qualitative detection of IgG oligoclonal banding in CSF and serum for multiple sclerosis diagnosis, with 100-fold increased sensitivity versus standard immunofixation. For neurology and multiple sclerosis testing laboratories.
• Connective Tissue Diseases Test Panel Comprehensive panel including ANA HEp-2 IFA, ANADetect, ANAscreen, anti-dsDNA, anti-histone, anti-nucleosome, anti-Jo-1, anti-Scl-70, anti-SS-A, anti-SS-B, anti-RNP/Sm, and anti-centromere B tests for CTD diagnosis including SLE, Sjogren's, and systemic sclerosis. For autoimmune disease testing laboratories.
• Antiphospholipid Syndrome Test Panel Largest portfolio of ELISA-based tests for APS diagnostics including anti-cardiolipin, anti-beta-2-glycoprotein I, anti-prothrombin, anti-phosphatidyl serine, anti-phosphatidyl inositol, anti-phosphatidic acid, and anti-annexin V antibodies. For autoimmune disease testing laboratories.
• Vasculitis Test Panel
• Sebia Academy Educational service providing scientific and medical educational information including webinars, publications, and training resources for customers worldwide. For clinical laboratory professionals using Sebia products.
• Sebia Lean Service Modular and scalable laboratory optimization service designed to enhance laboratory performance with customized product and management solutions. For clinical laboratories using Sebia products.
• Sebia Service Technical and scientific support service providing daily assistance for laboratory professionals using Sebia products. For clinical laboratory customers.

Quantifiable outcome

• Clinical performance of 96.8% concordance for FLC testing based on IMWG criteria
• +2 more outcomes

Named customers8 records

Segments6 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability2 records

Feature6 records

Partnerships

Five partnerships are on record, tiered core.

• ABIONYX PharmacoreStrategic or Co-development Partner · 20 November 2025Exclusive global strategic partnership focused on developing new diagnostic tests for early detection and monitoring of sepsis. Combines Sebia's expertise in blood sample analysis with ABIONYX Pharma's lipid biology and clinical studies capabilities.
• Inpeco FlexLabcoreTechnology or IntegrationCAPILLARYS 3 TERA TLA connects to Inpeco FlexLab automation track enabling total lab automation integration for high-volume laboratories.
• Siemens Healthineers AptiocoreTechnology or IntegrationCAPILLARYS 3 TERA TLA connects to Siemens Healthineers Aptio automation track enabling total lab automation integration.
• ORGENTEC DiagnostikacoreStrategic or Co-development PartnerSebia acquired ORGENTEC Diagnostika from Water Street Healthcare Partners in 2021, expanding capabilities in autoimmunity, infectious diseases, and clinical trials. ORGENTEC had previously acquired Arotec and Corgenix.
• ZEUS ScientificcoreStrategic or Co-development PartnerSebia acquired ZEUS Scientific in 2022, a New Jersey-based IVD company specializing in autoimmune and infectious diseases including Lyme disease, expanding Sebia's presence in the U.S. market.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Helena Laboratories: Long-established US specialty manufacturer of clinical electrophoresis and hemostasis instruments and reagents. Directly comparable to Sebia's CAPILLARYS and HYDRASYS platforms, especially in protein electrophoresis and hemoglobinopathy screening.
• Tosoh Bioscience: Specialty diagnostics division offering HPLC-based HbA1c analyzers (G8, G11) and immunoassay systems that directly compete with Sebia's HbA1c electrophoresis and Alegria 2 ELISA offerings.
• The Binding Site (Thermo Fisher Scientific): Specialty immunology diagnostics company (acquired by Thermo Fisher) historically strongest in Freelite free light chain assays for multiple myeloma—directly competitive with Sebia's FLC Kappa & Lambda offering for plasma cell disorders.

Broad incumbents

• Siemens Healthineers: Major IVD incumbent whose Aptio automation track integrates with Sebia's CAPILLARYS 3 TERA TLA, while also competing in HbA1c, hemoglobin, and broader clinical chemistry. Significant overlap in hospital lab tenders.
• Roche Diagnostics: Largest global IVD player with broad menus in HbA1c, clinical chemistry, and autoimmune serology. Competes with Sebia in diabetes monitoring and increasingly in specialty protein diagnostics through its cobas platform.
• Bio-Rad Laboratories: Diversified life science and clinical diagnostics company with a clinical electrophoresis product line (VARIANT, D-10) overlapping Sebia's hemoglobin and HbA1c testing. Larger portfolio and broader geographic reach make it a broad incumbent rather than direct niche competitor.
• Beckman Coulter (Danaher): Major IVD platform player with broad clinical chemistry, immunoassay, and hematology offerings that overlap with Sebia's HbA1c and hemoglobin testing, plus autoimmune serology menus.
• Abbott Diagnostics: Global IVD incumbent with overlapping HbA1c and clinical chemistry offerings on the ARCHITECT/Alinity platforms. Competes in hospital lab menus where Sebia's electrophoresis reagents are also positioned.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/106560

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries3 records

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sebia